RedHill Accelerates Opaganib's Nuclear Radiation Protection Program - Positive Data Published
The publication highlights observations from numerous studies undertaken in both protection against radiation toxicity and cancer radiotherapy settings.
- The publication highlights observations from numerous studies undertaken in both protection against radiation toxicity and cancer radiotherapy settings.
- Much of the damage caused by radiation exposure is caused by inflammation secondary to the effects of ionizing radiation itself known as Acute Radiation Syndrome.
- Again, opaganib was not associated with a diminished tumor response to fractionated radiation treatment and increased weight loss from radiation treatment was not observed.
- Data from the opaganib global Phase 2/3 study has been submitted for peer review and recently published in medRxiv .